{"id":621,"action":"update","user":"jmcmichael","created_at":"2015-04-16T17:18:59.726Z","changes":{"name":["Imatinib Resistance UPDATED2","Imatinib Resistance UPDATED3"],"description":["While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. UPDATED2","While imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. UPDATED3"]},"diffs":{"name":"\u003cdiv class=\"diff\"\u003e\n  \u003cul\u003e\n    \u003cli class=\"del\"\u003e\u003cdel\u003eImatinib Resistance UPDATED\u003cstrong\u003e2\u003c/strong\u003e\u003c/del\u003e\u003c/li\u003e\n    \u003cli class=\"ins\"\u003e\u003cins\u003eImatinib Resistance UPDATED\u003cstrong\u003e3\u003c/strong\u003e\u003c/ins\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n","description":"\u003cdiv class=\"diff\"\u003e\n  \u003cul\u003e\n    \u003cli class=\"del\"\u003e\u003cdel\u003eWhile imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. UPDATED\u003cstrong\u003e2\u003c/strong\u003e\u003c/del\u003e\u003c/li\u003e\n    \u003cli class=\"ins\"\u003e\u003cins\u003eWhile imatinib has shown to be incredibly successful in treating philadelphia chromosome positive CML, patients that have shown primary or secondary resistance to the drug have been observed to harbor T315I and E255K ABL kinase domain mutations. These mutations, among others, have been observed both in primary refractory disease and acquired resistance. In gastrointestinal stromal tumors (GIST), PDGFRA 842 mutations have also been shown to confer resistance to imatinib. UPDATED\u003cstrong\u003e3\u003c/strong\u003e\u003c/ins\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n"}}
